End-of-day quote
Mexican S.E.
23:00:00 11/06/2024 BST
5-day change
1st Jan Change
16.46
MXN
-5.67%
-7.99%
+16.24%
Ex-dividend day for interim dividend
A dividende intermédiaire is removed today from 's share.
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
04-25
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-24
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2023 Earnings Call, Feb 22, 2024
02-22
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-21
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2023
02-21
CI
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America
11-29
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2023 Earnings Call, Oct 26, 2023
26/10/23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
24/10/23
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2023 Earnings Call, Jul 27, 2023
27/07/23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
26/07/23
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2023 Earnings Call, Apr 27, 2023
27/04/23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2023
27/04/23
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V. - Analyst/Investor Day
08/03/23
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q4 2022 Earnings Call, Feb 23, 2023
23/02/23
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
22/02/23
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Full Year Ended December 31, 2022
22/02/23
CI
IFC and Genomma Lab Sign Multi-Currency Long-Term Loan to Boost Access to OTC Medicines in Latin America and the Caribbean Region
09/01/23
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces CEO Changes
28/11/22
CI
Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes
28/11/22
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q3 2022 Earnings Call, Oct 27, 2022
27/10/22
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
26/10/22
CI
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
25/10/22
CI
Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q2 2022 Earnings Call, Jul 28, 2022
28/07/22
Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013.
27/07/22
CI
Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
27/07/22
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
More about the company
Last Close Price
16.46
MXN
Average target price
19.5
MXN
Spread / Average Target
+18.47%
Consensus
1st Jan change
Capi.
+16.24% 828M +49.93% 781B -7.38% 350B +18.12% 330B +7.40% 293B +16.91% 248B +0.53% 221B +11.06% 217B +3.38% 162B -4.22% 157B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1